id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-N-0238-0028,FDA,FDA-2006-N-0238,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; Expanded Access to Investigational Drugs for Treatment Use",Notice,NAL-Notice of Approval,2011-03-03T05:00:00Z,2011,3,2011-03-03T05:00:00Z,,2015-06-02T17:59:33Z,2011-04739,0,0,0900006480bfe012
FDA-2006-N-0238-0027,FDA,FDA-2006-N-0238,"OMB Review [12866], Expanded Access to INDs,  Final Rule Published 8/13/09",Other,References (internal) (REF),2009-08-24T04:00:00Z,2009,8,2009-08-24T04:00:00Z,,2025-04-11T22:14:10Z,,0,0,0900006480a0c8f0
FDA-2006-N-0238-0026,FDA,FDA-2006-N-0238,Expanded Access to Investigational Drugs for Treatment Use,Rule,NFR-Notice of Final Rule,2009-08-13T04:00:00Z,2009,8,2009-08-13T04:00:00Z,,2015-06-02T18:01:51Z,E9-19005,0,0,0900006480a084e7
FDA-2006-N-0238-0019,FDA,FDA-2006-N-0238,Letter from Cancer Leadership Council (CLC) to  FDA /CDER,Other,Letter(s),2008-12-16T05:00:00Z,2008,12,2008-12-16T05:00:00Z,,2025-04-11T22:27:16Z,,0,0,0900006480744556
FDA-2006-N-0238-0018,FDA,FDA-2006-N-0238,OMB Changes of the Proposed Rule FDA Regulations Policy and Management Staff to the Division of Dockets Management,Supporting & Related Material,Reference (internal unless indicated),2008-10-14T04:00:00Z,2008,10,,,2025-04-14T17:07:08Z,,0,0,0900006480456b60
FDA-2006-N-0238-0017,FDA,FDA-2006-N-0238,Reference 1 OMB Changes of FDA Regulations Policy and Management Staff to the Division of Dockets Management,Supporting & Related Material,Reference (internal unless indicated),2008-10-10T04:00:00Z,2008,10,,,2025-04-14T16:59:59Z,,0,0,0900006480456cc2
FDA-2006-N-0238-0008,FDA,FDA-2006-N-0238,Attachment 1 Creation and Development of the Public Service Orphan Drug Human Botulism Immune Globulin re Comment from California Department of Health Services,Supporting & Related Material,C-Comment (Supporting and Related Material),2007-03-19T04:00:00Z,2007,3,,,2025-04-14T16:49:35Z,,0,0,0900006480456e00
FDA-2006-N-0238-0010,FDA,FDA-2006-N-0238,Attachment 2 Human Botulism Immune Globulin for the Treatment of Infant Botulism re Comment from California Department of Health Services,Supporting & Related Material,C-Comment (Supporting and Related Material),2007-03-19T04:00:00Z,2007,3,,,2025-04-14T16:50:01Z,,0,0,0900006480456e03
FDA-2006-N-0238-0006,FDA,FDA-2006-N-0238,Memorandum from Office of Policy to the Division of Dockets Management Request for Extension Comment Period,Other,Memorandum,2007-03-13T04:00:00Z,2007,3,2007-03-12T04:00:00Z,,2025-04-11T22:24:04Z,,0,0,0900006480456d95
FDA-2006-N-0238-0001,FDA,FDA-2006-N-0238,Expanded Access to Investigational Drugs for Treatment Use,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2006-12-14T00:00:00Z,2006,12,2006-12-14T05:00:00Z,2007-03-15T03:59:59Z,2025-05-21T09:01:14Z,06-9684,0,0,0900006480456c8f